Eli Lilly Presents P-III Clinical Development Program Results of Lebrikizumab for Atopic Dermatitis at 5th Annual RAD Congress
- The secondary analysis from the P-III trial (Advocate 1& 2) in 869 patients evaluating lebrikizumab vs PBO. The (ADhere) study evaluating lebrikizumab + TCS vs PBO + TCS in 228 patients
- In 16wk. induction periods, the results showed an improvement or clearance of the face (62% vs 32% & 58% vs 22%) in the (Advocate 1& 2) study; 69% vs 46% in (ADhere) study, or hand dermatitis (67% vs 29% & 62% vs 19%) and 73% vs 43%, respectively. An additional secondary analysis demonstrated stable & long-lasting results of lebrikizumab (q4w or q2w)
- 80% in (ADvocate 1 & 2) trial maintained EASI-75 response, 70% maintained EASI-75 response with no or minimal fluctuations across 10 study visits @1yr. Lilly & partner Almirall S.A. expect regulatory decisions in the US & EU in 2023
Ref: Eli Lilly | Image: Eli Lilly
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.